FibroGen, Inc.
FGEN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.33 | 1.04 | 0.00 | -2.28 |
| FCF Yield | -10.44% | -14.73% | -0.49% | -0.35% |
| EV / EBITDA | -9.58 | -7.25 | -132.29 | -97.33 |
| Quality | ||||
| ROIC | -184.87% | -146.59% | -86.80% | -51.59% |
| Gross Margin | 47.47% | 91.53% | 85.59% | -90.89% |
| Cash Conversion Ratio | 2.90 | 1.11 | 0.50 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.52% | -41.63% | -7.24% | 6,173,609.35% |
| Free Cash Flow Growth | 56.46% | -71.95% | -64.27% | -244.85% |
| Safety | ||||
| Net Debt / EBITDA | -0.28 | -0.19 | 0.23 | 0.21 |
| Interest Coverage | -18.24 | -39.87 | -209.05 | -268.40 |
| Efficiency | ||||
| Inventory Turnover | 4.93 | 0.10 | 0.50 | 14.48 |
| Cash Conversion Cycle | -38.85 | 2,494.77 | 216.46 | 43.40 |